Fast Track Designations:
Six-Year Trends and Strategic Insights
Fast Track Designations
Fast Track is an FDA process that speeds up the development and review of drugs for serious conditions with unmet medical needs, helping patients access important new treatments sooner. Serious conditions include life-threatening diseases like cancer and AIDS, as well as chronic illnesses such as diabetes, epilepsy, and depression. An unmet medical need means either no approved treatment exists, or the new drug may offer significant improvement over existing options.
Drugs with Fast Track designation receive closer FDA support through more frequent meetings and written guidance during development. They may also qualify for Accelerated Approval, Priority Review, and Rolling Review, allowing companies to submit completed parts of an application early instead of waiting for the full package. Drug companies must request Fast Track status, and the FDA decides within 60 days based on whether the drug treats a serious condition and addresses an unmet medical need. This early, ongoing communication often speeds up approval and patient access.
Fast Track Designations Over the Past Six Years (2020–2025)
Fast Track designations, which are granted by the FDA to expedite the development and review of therapies addressing serious conditions and unmet medical needs, have shown a fluctuating but sharply accelerating trend over the past six years.
From 2020 to 2022, the number of designations remained relatively modest and slightly volatile, with 17 in 2020, a marginal increase to 18 in 2021, followed by a dip to 12 in 2022. This period reflects a comparatively stable regulatory environment post-pandemic onset, with steady but restrained uptake of expedited pathways.
In 2023 and 2024, there was a clear upward shift, with designations rising to 25 in 2023 and further to 31 in 2024, indicating renewed momentum in drug development pipelines, particularly in oncology, rare diseases, and advanced biologics.
The most striking change comes in 2025, where Fast Track designations surged dramatically to 155 drugs, marking an unprecedented spike compared to previous years. This sharp increase highlights a significant acceleration in FDA engagement with innovative therapies, likely driven by a combination of expanded biotech pipelines, increased focus on unmet needs, and greater reliance on expedited regulatory pathways.
Six-Year Trend in Fast Track Designations (2020–2025)
Fig 1: Fast track designation trends
A notable portion of 2025 designations included cutting-edge therapies across multiple areas. Examples include drugs such as penpulimab-kcqx, an immunotherapy candidate, Journavx for pain management, and Ekterly and Gomekli, among others spanning oncology, infectious diseases, and rare conditions.